CD274 and cancer: Immune checkpoint blockade (ICB) therapies targeting the programmed cell death protein 1 (PD1)/programmed cell death ligand 1 (PD-L1)70,71 pathway or cytotoxic T lymphocyte antigen 4 (CTLA4)72–74 have revolutionized the treatment landscape for multiple cancer types.